NSE · PARNAXLAB
Parnax Lab Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹3 Cr with net profit ₹1 Cr — a 33.07% net margin, versus -220% the period before.
Shareholding
As of 2026-06-30
- Promoter72.3%
- Public27.7%
3,572 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.44× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #27 of 50 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,87,521 Cr | 84.04 | 22.3 | 25.49% | 13.95% |
| Gland Pharma Limited | ₹48,614 Cr | 42.43 | 4.69 | 9.92% | 16.78% |
| Ajanta Pharma Limited | ₹43,986 Cr | 38.76 | 9.72 | 23.33% | 19.65% |
| Rubicon Research Limited | ₹29,630 Cr | 102.81 | 22.99 | 19.14% | 14.89% |
| Caplin Point Laboratories Ltd. | ₹21,248 Cr | 31.94 | 6.31 | 17.88% | 29.09% |
| Eris Lifesciences Limited | ₹18,800 Cr | 28.62 | 4.82 | 15.87% | 20.04% |
| Shilpa Medicare Ltd. | ₹18,383 Cr | 64.64 | 7.09 | 9.39% | 17.67% |
| Marksans Pharma Limited | ₹14,973 Cr | 28.98 | 4.95 | 13.82% | 16.29% |
| Bliss GVS Pharma Ltd. | ₹7,448 Cr | 54.09 | 6.24 | 10.82% | 13.55% |
| Senores Pharmaceuticals Limited | ₹6,738 Cr | 53.32 | 7.22 | 12.36% | 18.59% |
| Parnax Lab Ltd.(this company) | ₹146 Cr | 14.62 | 1.54 | 12.38% | 3.55% |
AI analysis
AI-generated · google/gemini-2.5-flashParnax Lab Ltd. is listed with a market capitalization of Rs 164 Cr. The company reported an EPS of 11.14 and a PE ratio of 12.85. The book value stands at Rs 82.83, with a Return on Equity (ROE) of 12.38% and a Return on Capital Employed (ROCE) of 12.15%. Debt to equity is 0.97. For the fiscal year ending Mar 2025, revenue was Rs 189.41 Cr, and net profit was Rs 11.52 Cr.
Positives
- +The profit margin is high at 474.35%.
- +Return on Equity (ROE) stands at 12.38%.
- +Return on Capital Employed (ROCE) is 12.15%.
Negatives
- −The promoter holding pledge is 9.41% as of June 30, 2026.
- −The debt-to-equity ratio is 0.97, indicating reliance on debt financing.
- −The company has not disclosed quarterly results since Mar 2026.
Financial Performance
For the fiscal year ending Mar 2025, Parnax Lab Ltd. reported revenue of Rs 189.41 Cr and a net profit of Rs 11.52 Cr. Quarterly results show revenue of Rs 69.63 Cr and a net profit of Rs 2.18 Cr for the quarter ending Mar 2026. The EBITDA for the same quarter was Rs 4.84 Cr.
Profitability & Returns
The company's profit margin stood at 474.35%. Return on Equity (ROE) for Parnax Lab Ltd. is 12.38%, and Return on Capital Employed (ROCE) is 12.15%. The earnings per share (EPS) is 11.14.
Balance Sheet
Parnax Lab Ltd. has a debt-to-equity ratio of 0.97. The book value per share is Rs 82.83. The market capitalization is Rs 164 Cr.
Ownership & Pledges
As of June 30, 2026, promoter holding in Parnax Lab Ltd. is 72.30%, while public shareholding is 27.70%. A total of 9.41% of promoter shares are pledged. Specifically, 390,744 shares held by Binoy Baiju Shah (28.53% of total) and 390,744 shares held by Mihir Prakash Shah (34.24% of total) are pledged.
Data as of — price: 2026-09-10 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.